- Home
- DUOL vs RPRX Comparison
DUOL vs RPRX Comparison
Compare DUOL & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DUOL
- RPRX
- Stock Information
- Founded
- DUOL 2011
- RPRX 1996
- Country
- DUOL United States
- RPRX United States
- Employees
- DUOL N/A
- RPRX N/A
- Industry
- DUOL Computer Software: Prepackaged Software
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- DUOL Technology
- RPRX Health Care
- Exchange
- DUOL Nasdaq
- RPRX Nasdaq
- Market Cap
- DUOL 13.3B
- RPRX 15.6B
- IPO Year
- DUOL 2021
- RPRX 2020
- Fundamental
- Price
- DUOL $285.11
- RPRX $35.15
- Analyst Decision
- DUOL Buy
- RPRX Strong Buy
- Analyst Count
- DUOL 18
- RPRX 3
- Target Price
- DUOL $415.12
- RPRX $45.33
- AVG Volume (30 Days)
- DUOL 2.0M
- RPRX 3.9M
- Earning Date
- DUOL 11-05-2025
- RPRX 11-05-2025
- Dividend Yield
- DUOL N/A
- RPRX 2.50%
- EPS Growth
- DUOL 73.11
- RPRX 54.86
- EPS
- DUOL 2.46
- RPRX 2.32
- Revenue
- DUOL $885,152,000.00
- RPRX $2,305,243,000.00
- Revenue This Year
- DUOL $38.77
- RPRX $33.77
- Revenue Next Year
- DUOL $26.49
- RPRX $4.62
- P/E Ratio
- DUOL $116.06
- RPRX $15.12
- Revenue Growth
- DUOL 39.51
- RPRX 3.02
- 52 Week Low
- DUOL $227.65
- RPRX $24.05
- 52 Week High
- DUOL $544.93
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- DUOL 40.14
- RPRX 40.78
- Support Level
- DUOL $256.63
- RPRX $35.97
- Resistance Level
- DUOL $319.68
- RPRX $36.94
- Average True Range (ATR)
- DUOL 16.53
- RPRX 0.85
- MACD
- DUOL 2.15
- RPRX -0.06
- Stochastic Oscillator
- DUOL 41.11
- RPRX 33.46
About DUOL Duolingo Inc.
Duolingo Inc is a technology company that develops a mobile learning platform to learn languages and is the top-grossing app in the Education category on both Google Play and the Apple App Store. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated master new material, and achieve their learning goals. Its solutions include the Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has four predominant sources of revenue; time-based subscriptions, in-app advertising placement by third parties, and the Duolingo English Test, and In-App Purchases.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.